Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (889)	2/5/2002 1:08:17 PM
From: scaram(o)uche	Respond to of 2243

Evan C. Unger, MD Chairman, President, and Chief Executive Officer Dr. Unger was founder, President and CEO of the predecessor company ImaRx Pharmaceuticals. That company, founded in 1990, developed three FDA approved in vivo diagnostic agents. Dr. Unger sold that company to DuPont Pharmaceuticals for about $40 Million. Dr. Unger then founded ImaRx Therapeutics in 2000, raising $6.3 Million in venture and angel funding. Dr. Unger is a world-renowned expert on diagnostic imaging, contrast media development and drug delivery. He has over 80 publications in peer-reviewed journals and more than 140 abstracts presented at major scientific meetings; he is the principal inventor on the majority of the Company's U.S. and foreign patents. He serves as associate editor of Radiology, editor of the journals Academic Radiology and Magnetic Resonance Imaging, guest editor of Investigative Radiology and reviewer for the Journal of Magnetic Resonance Imaging, and Nature Biotechnology. Dr. Unger is a board-certified radiologist and is Professor of Radiology at the University of Arizona Health Sciences Center where he has a flexible appointment in which he spends about four days a month teaching, doing clinical work and research. Dr. Unger has an undergraduate degree in Economics, with Departmental Honors from the University of California at Berkeley. His medical degree is from the University of California, San Francisco, graduating with honors Alpha Omega Alpha. Gregg Cobb, BSc, JD, MBA Chief Financial Officer Mr. Cobb oversees the financial, accounting, systems, human resources and other administrative activities for the Company. Mr. Cobb joined the Company in 2001. He has an undergraduate degree in computer sciences engineering, a law degree and an M.B.A. Mr. Cobb has worked for several years in the Venture Capital industry and has written or evaluated hundreds of business plan. With Mr. Cobb's help, ImaRx has developed its business and financial strategy to maximize growth and shareholder value. Nina Ossanna, PhD Senior Director, Business Development Dr. Ossanna is the Company's Senior Director for Business Development. Prior to joining ImaRx in 2001, Dr. Ossanna was the Director of the Office of Technology Licensing at Johns Hopkins University School of Medicine, where she oversaw and was responsible for all transactional and intellectual property matters for the School. Dr. Ossanna also served as an examiner at the United States Patent Office, examining patents filed in biotechnology. Dr. Ossanna earned a Ph.D. in Molecular Biology from the University of Arizona and is registered to practice before the United States Patent Office. Rajan Ramaswami, PhD Vice President, Research and Development Dr. Ramaswami directs the Company's analytical chemistry laboratories for drug discovery and also manages all product and process development related to ImaRx products. Dr. Ramaswami received his MS-PhD in Polymer Chemistry from Carnegie-Mellon University, and was a postdoctoral research at fellow at the University of Arizona, Department of Chemistry. Dr. Ramaswami joined ImaRx in 1992.